Pfizer Inc. (NYSE:PFE) Shares Sold by NuWave Investment Management LLC


Share on StockTwits

NuWave Investment Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 25.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,098 shares of the biopharmaceutical company’s stock after selling 370 shares during the period. NuWave Investment Management LLC’s holdings in Pfizer were worth $40,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Two Sigma Advisers LP grew its holdings in Pfizer by 74.8% during the 2nd quarter. Two Sigma Advisers LP now owns 11,066,501 shares of the biopharmaceutical company’s stock valued at $361,875,000 after purchasing an additional 4,736,500 shares in the last quarter. Natixis grew its stake in Pfizer by 528.1% in the 3rd quarter. Natixis now owns 3,814,480 shares of the biopharmaceutical company’s stock valued at $139,991,000 after buying an additional 3,207,172 shares during the last quarter. Morgan Stanley boosted its holdings in Pfizer by 6.4% in the 3rd quarter. Morgan Stanley now owns 46,069,866 shares of the biopharmaceutical company’s stock valued at $1,690,763,000 after purchasing an additional 2,777,676 shares during the period. Robeco Institutional Asset Management B.V. boosted its holdings in Pfizer by 36.1% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 9,794,442 shares of the biopharmaceutical company’s stock valued at $359,457,000 after purchasing an additional 2,599,629 shares during the period. Finally, Retirement Systems of Alabama lifted its holdings in shares of Pfizer by 57.9% during the 3rd quarter. Retirement Systems of Alabama now owns 3,749,383 shares of the biopharmaceutical company’s stock worth $137,602,000 after acquiring an additional 1,374,298 shares during the period. 69.08% of the stock is owned by institutional investors and hedge funds.

In other Pfizer news, major shareholder Pfizer Inc acquired 1,200,000 shares of the business’s stock in a transaction dated Tuesday, October 27th. The shares were acquired at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the transaction, the insider now directly owns 27,349,211 shares in the company, valued at approximately $273,492,110. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.08% of the company’s stock.

A number of brokerages recently issued reports on PFE. JPMorgan Chase & Co. set a $36.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, November 9th. Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 price objective for the company. TheStreet upgraded shares of Pfizer from a “c+” rating to a “b-” rating in a research report on Wednesday, November 25th. Atlantic Securities cut shares of Pfizer from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $44.00 to $39.00 in a research report on Monday, October 12th. Finally, Royal Bank of Canada set a $42.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, January 4th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $39.87.

Shares of NYSE:PFE opened at $36.86 on Thursday. Pfizer Inc. has a one year low of $27.88 and a one year high of $43.08. The company has a 50 day moving average of $38.25 and a 200-day moving average of $37.19. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16. The stock has a market cap of $204.88 billion, a price-to-earnings ratio of 14.63, a P/E/G ratio of 3.10 and a beta of 0.66.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.01. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The business had revenue of $12.13 billion for the quarter, compared to analyst estimates of $12.30 billion. During the same quarter last year, the firm earned $0.75 EPS. Pfizer’s quarterly revenue was down 4.3% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.84 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 5th. Shareholders of record on Friday, January 29th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Thursday, January 28th. This represents a $1.56 dividend on an annualized basis and a yield of 4.23%. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s payout ratio is presently 51.53%.

About Pfizer

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Featured Article: Is it better to buy a fund with a higher or lower NAV?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.